The FDA has released 21 revised and 13 new product-specific draft guidelines designed to promote the development of generic drugs, bringing the total number of such guidelines issued by the agency to 1,974. The guidelines explain the FDA's expectations for the studies required to prove the equivalence of a generic drug to a reference-listed drug.